Altimmune, Inc. (ALT) earnings date
Mar 4, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 43 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 12, 2026 | before open | 43 | 8-K |
| Q2 FY2026 | Wed, Aug 12, 2026 | before open | 43 | 8-K |
| Q1 FY2026 | Wed, May 13, 2026 | before open | 43 | 8-K |
| Q4 FY2025 | Thu, Mar 5, 2026 | before open | 64 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Tue, Aug 12, 2025 | before open | 43 | 8-K |
| Q1 FY2025 | Tue, May 13, 2025 | before open | 43 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | before open | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "Enrollment is complete in the RESTORE Phase 2 trial in ALD, with topline data expected in the second half of 2027 Scientific Data on Pemvidutide in MASH and AUD Presented at AASLD The Liver Meeting® 2026" exhibit |
| Q3 FY2026 | "Net loss for the three months ended September 30, 2026, was $31.6 million, or $0.15 net loss per share, compared to a net loss of $19.0 million, or $0.21 net loss per share, in the same period in 2025 Conference Call Information: Date: November 12, 2026 Time: 8:30 a.m. Eastern Time Webcast: To listen, the conference call will be webcast live on Altimmune’s Investor Relations (IR) website at https://ir.altimmune.com/investors ." exhibit |
| Q2 FY2026 | "In July 2026, the Company completed patient enrollment in the RESTORE Phase 2 trial of pemvidutide in ALD o The RESTORE trial is a 48-week study evaluating the safety and efficacy of pemvidutide versus placebo in approximately 120 patients with liver disease due to excessive alcohol consumption o The trial enrolled patients with ALD and a history of chronic and heavy drinking at baseline o To support future regulatory discussions, the Company has amended the trial protocol to more fully evaluate the liver benefits pemvidutide may provide after one year of treatment in the ALD population o The " exhibit |
| Q2 FY2026 | "Net loss for the three months ended June 30, 2026, was $22.8 million, or $0.12 net loss per share, compared to a net loss of $22.1 million, or $0.27 net loss per share, in the same period in 2025 Conference Call Information: Date: August 12, 2026 Time: 8:30 a.m. Eastern Time Webcast: To listen, the conference call will be webcast live on Altimmune’s Investor Relations (IR) website at https://ir.altimmune.com/investors ." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ALT
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ALT
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ALT/"><img src="https://veritasdata.dev/embed/ALT.svg" alt="ALT earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ALT/)
Script
<script async src="https://veritasdata.dev/embed/ALT.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ALT"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.